Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company focusing on oncology therapeutics with a strong China root and global vision. We have developed a strong oncology-focused pipeline of drug candidates, including ADCs, oncolytic virus drugs and immunotherapies at clinical and pre-clinical stages. We plan to commercialize our pipeline products in China through dedicated sales and marketing forces and in overseas markets, such as the U.S. and European markets, via partnerships.
Dr. Pu Zhongjie is the founder and Controlling Shareholder of the Group, serving as our executive Director and the chairman of our Board, director and the chairman of the board of Taizhou Aoke, director of Miracogen Shanghai and executive director of Lepu Beijing.
In addition to his position at Lepu Biopharma, Dr. Pu has consecutively held positions with Lepu Medicalas its director, chief technology officer, general manager, vice chairman of the board and chairman of the board and is currently the chief technology officer and chairman of the board of Lepu Medical. Dr. Pu also serves as an executive director of Beijing Tiandi Harmony Technology Co., Ltd. (北京天地和協科技有限公司), a wholly owned subsidiary of Lepu Medical engaging in the medical device business. Further, Dr. Pu has been serving as an executive director and the general manager of Beijing Puping Tiancheng Investment Management Consulting Co., Ltd. (北京普平天成投資管理顧問有限公司), a company ultimately owned by Dr. Pu as to 100% and licensed to conduct investment consulting business, In addition, Dr. Pu has also been serving as an executive director and the general manager of Huarui Zongheng, an executive director and the general manager of Beijing Houde Yimin, an executive director and the general manager of Ningbo Houde Yimin, an executive director and the general manager of Ningbo Houde Yimin Investment Management Co., Ltd. (寧波厚德義民投資管理有限公司), a company wholly owned by Beijing Houde Yimin, and served as an independent director of Beijing Jinyi Culture Development Joint Stock Company (北京金一文化發展股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002721). Prior to establishing Lepu Biopharma, Dr. Pu served as deputy general manager of technology department of U.S. WP Medical Technologies, Inc.
Dr. Pu obtained a bachelor’s degree in mechanical engineering in metal materials from Xi’an Jiaotong University (西安交通大學) in the PRC in 1983, a master’s degree in metal materials from Xi’an Jiaotong University (西安交通大學) in the PRC in 1985, and a doctoral degree in metal materials from Central Iron & Steel Research Institute (鋼鐵研究總院) in the PRC in July 1990.
Dr. Sui Ziye is our executive Director and the chief executive officer of our Company, a director of Miracogen Shanghai, a director of Taizhou Aoke, an executive director of CtM Bio, and the general manager of Lepu Beijing. In addition, Dr. Sui also serves as a director of Hangzhou HealSun, a company owned by us as to 23.2% and a non-executive director of Star Combo Pharma Limited, a company listed on the Australian Stock Exchange (stock code: S66). Dr. Sui has nearly ten years of managerial experience in the pharmaceutical sector.
Prior to joining our Group, Dr. Sui held several positions at Lepu Medical and its subsidiaries, including an international sales & marketing manager and a vice president of Lepu Medical, a CEO of Comed BV, a CEO of Beijing Lepu Hushengtang Technology Co., Ltd. (北京樂普護生堂網絡科技有限公司), an executive director of Beijing Star GK Medical Device Co., Ltd. (北京思達醫用裝置有限公司), the chairman of the board of Zhongcheng Healthcare Industrial (Hainan) Co., Ltd. (中鋮健康產業(海南)股份有限公司), previously known as Hainan Mingshengda Pharmaceutical Co., Ltd. (海南明盛達藥業有限公司), and a director of Beijing Quinovare Medical Technology Co., Ltd. (北京快舒爾醫療技術有限公司).
Dr. Sui obtained a bachelor’s degree in medical science from Peking University (北京大學) in the PRC in 2001 and a doctoral degree from University of Rochester in the U.S. in 2007.
Dr. Hu Chaohong is our executive Director and co-chief executive officer of our Company, chairman of the board and general manager of Miracogen Shanghai, a company founded by Dr. Hu in 2014, and director of Innocube Limited. Dr. Hu has over twenty years of industry experience in development of therapeutic antibodies, antibody drug conjugates and vaccines.
Prior to founding Miracogen Shanghai, Dr. Hu served as Director of Bioassay Development and Process Analytics department at Seagen Inc. (previously known as Seattle Genetics Inc.), a company listed on the Nasdaq Stock Exchange (stock code: SGEN), from June 2007 to October 2013, the head of Molecular Biology and Clinical Immunology department at GlaxoSmithKline plc, a company listed on the New York Stock Exchange (stock code: GSK), research scientist and then Director of Molecular Biology and Clinical Immunology department at ID Biomedical Corporation, , previously known as ID Vaccine Corporation, a company listed on the Nasdaq Stock Exchange (stock code: IDBE) and delisted in 2005, a postdoctoral fellow at the University of Washington.
Dr. Hu obtained a bachelor of science degree in biochemistry from Wuhan University (武漢大學) in the PRC in 1986 and a Ph.D degree in science from Institute of Biophysics, Chinese Academy of Sciences (中國科學院生物物理研究所) in 1991. Dr. Hu was awarded the second prize of National Natural Science Award (國家自然科學二等獎) by the State Council of the PRC (國務院) in 1995.
Dr. Qin Minmin Prior to joining our Group, Dr. Qin served as senior vice president and head of CMC department of Harbour BioMed Holdings Limited (和鉑醫藥控股有限公司), vice president of Wuxi Biologics (Cayman) Inc. (藥明生物技術有限公司), chief scientific officer of Jiangsu Pacific Meinuoke Pharmaceutical Co., Ltd. (江蘇太平洋美諾克生物藥業有限公司), chief technology officer as well as senior vice president of Zhejiang Teruisi Pharmaceutical Co., Ltd. (浙江特瑞思藥業股份有限公司), chief technology officer of JMT-Bio, senior director of Five Prime Therapeutics, and senior director of process development at BioMarin Pharmaceutical Inc.
Dr. Qin obtained a bachelor’s degree in agriculture from Northwest Agriculture and Forest University (西北農林科技大學), previously known as Northwest Agriculture College (西北農學院) in the PRC in 1981, a doctoral degree from University of Wisconsin Madison in the U.S. in 1991, and completed post-doctoral research from the University of California Berkeley in the U.S. in 1997.
Dr. Qin is an adjunct professor of Xi’an Jiaotong University (西安交通大學). Dr. Qin was awarded Rusty Award from Five Prime Therapeutics in both 2010 and 2011.
Dr. Li Hu is the vice president of our Company and the vice president of Miracogen Shanghai. Dr. Li has more than twenty years in drug discovery and preclinical development, and is an expert in assay development, high throughput screening and translational sciences. Dr. Li has led our ADC preclinical biology team to successfully obtain IND clearance in US and China for multiple ADC candidates and successfully developed bioanalytical and immunogenicity assays for nonclinical and clinical programs.
Prior to joining our Group, Dr. Li served as a manager and group leader of GlaxoSmithKline plc.
Dr. Li obtained a bachelor’s degree in chemistry from Nanjing University (南京大學) in the PRC in 1986, a master’s degree in environmental chemistry from Research Centre for Eco-Environmental Sciences, Chinese Academy of Sciences (中國科學院生態環境研究中心) in the PRC in 1989, and a Ph.D degree in biochemistry from Bryn Mawr College in the U.S. in 1996.
Dr. Li received GlaxoSmithKline’s Exceptional Sciences Award in 2006 and GlaxoSmithKline’s Silver Medal Award in 2008 and 2013 separately. In 2016, Dr. Li was appointed as Expert of Shanghai Pudong Science and Technology Development Fund. In 2009, he was interviewed by Genetic Engineering and Biotechnology News Magazine on application of ADP-GLO technologies in drug screening. In 2004, he was invited as a member to the 6th Sino-American Technology Engineering Committee (中美工程技術研討會). He has co-authored over 20 scientific papers in peer-reviewed journals and is a co-inventor of several published patents.
Dr. Fang Lei is the vice president of our Company and the general manager of CtM Bio. Dr. Fang has more than ten years of experience in oncology clinical drug development and is an expert in immunology, development strategy and early-stage clinical trials for innovative drugs and translational medical science.
Prior to joining our Group, Dr. Fang served as director and then executive director of research and development department of I-Mab Biopharma Co., Ltd. (天境生物科技(上海)有限公司) and consecutively as a research fellow and scientist of GSK (Shanghai) Drug Development Co., Ltd. (葛蘭素史克(上海)醫藥研發有限公司).
Dr. Fang obtained a bachelor’s degree in biotechnology from Hebei University (河北大學) in the PRC in June 2004 and a doctoral degree in cell biology from Chinese Academy of Sciences (中國科學院). Dr. Fang received an R&D’s Exceptional Science Award (卓越科學成就獎) from GSK (Shanghai) Drug Development Co., Ltd. in 2013.
Dr. Tan Qian (谭茜), is the vice president of our Company. Dr. Tan has more than 15 years of extensive experience in pharmaceutical industry and leading healthcare and research institutions, and is an expert in oncology, precision cancer medicine, cancer genomics, drug development and clinical trials management with research interests focusing on the development, assessment and validation of novel therapeutic strategies for cancers including molecular targeted therapies.
Prior to joining our group, Dr. Tan served as the Chief Medical Officer at Yidu Cloud (Beijing) Technology Co., Ltd.* (医渡云（北京）技术有限公司) and senior oncology clinical research scientist and principal investigator at Princess Margaret Cancer Centre in Canada.
Dr. Tan obtained a bachelor's degree in medicine from Tiangjin Medical University (天津医科大学) in 1999, a master's degree in science from York University in Canada in 2009, a doctoral degree in oncology from University of Toronto in Canada in 2015, and completed a post-doctoral research from Stanford University in US in 2016.
Ms. Li Maggie Geman is the vice president of our Company and the vice general manager of Regulatory Affairs department of Miracogen Shanghai. Ms. Li has more than ten years of experience in regulatory affairs and drug registration in biopharmaceutics and oncology.
Prior to joining our Group, Ms. Li served as senior regulatory affairs specialist of Acucela Inc. and senior regulatory affairs specialist at Seattle Genetics Inc.
Ms. Li obtained a bachelor’s degree in chemical pharmaceuticals from Shengyang Pharmaceutical University(瀋陽藥科大學), previously known as Shenyang Pharmaceutical School(瀋陽藥學院), in the PRC in 1988 and a master’s degree in healthcare administration from the University of Washington in the US in 2006.
Ms. Li completed the certificate program in clinical trials from the University of Washington in 2007 and received the regulatory affairs certification accredited by the U.S. Regulatory Affairs Professionals Society in April 2008.